Sanofi stops breast cancer drug Amcenestrant Clinical Development Program - Video
|
Overview
Pharma major, Sanofi, has announced the discontinuation of the global clinical development program of amcenestrant, an investigational oral selective estrogen receptor degrader (SERD).
The decision is based on the outcome of a prespecified interim analysis of the Phase 3 AMEERA-5 trial evaluating amcenestrant in combination with palbociclib compared with letrozole in combination with palbociclib in patients with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer.
For more details click on the link given below :
Sanofi Halts Breast Cancer Drug Amcenestrant Clinical Development Program
Speakers
Roshni Dhar, a Mass com graduate with a soft corner for health happenings, joined Medical Dialogues as a news anchor in 2021. Inspired by her mother who is a gynaecologist, she likes to keep herself and the world updated on the occurring in the medical field. She covers various aspects of health news for MDTV at Medical Dialogues. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751
